CollPlant Biotechnologies (CLGN) Non Operating Income (2017 - 2026)
CollPlant Biotechnologies' (CLGN) quarterly Non Operating Income came in at $18000.0 in Q1 2026, down 90.82% YoY from $196000.0 in Q1 2025, and up 131.58% on a QoQ basis from -$57000.0 in Q4 2025.
CollPlant Biotechnologies (CLGN) Non Operating Income (2017 - 2026) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 10 years of Non Operating Income data on file, last reported at $18000.0 in Q1 2026.
- Quarterly Non Operating Income fell 90.82% year-over-year to $18000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$184000.0 (down 126.14% YoY) and the FY2025 annual result came in at -$6000.0, down 100.93% from the prior year.
- Non Operating Income improved to $18000.0 in Q1 2026, from -$57000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $379000.0 in Q4 2023 to a low of -$196000.0 in Q1 2023.
- A 5-year average of $77588.2 and a median of $89000.0 in 2022 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 759.38% in 2022, down 500.0% in 2022.
- Tracing CLGN's Non Operating Income over 5 years: stood at $275000.0 in 2022, then surged by 37.82% to $379000.0 in 2023, then slumped by 74.67% to $96000.0 in 2024, then sank by 159.38% to -$57000.0 in 2025, then surged by 131.58% to $18000.0 in 2026.
- The last three Non Operating Income figures came in at $18000.0 (Q1 2026), -$57000.0 (Q4 2025), and $24000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | CollPlant Biotechnologies | 4.26 Mn | 4.26 Mn | -243,000.00 | 18,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 30, 2026 | 18,000.00 |
| Dec 31, 2025 | -57,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Jun 30, 2025 | -169,000.00 |
| Mar 30, 2025 | 196,000.00 |
| Dec 31, 2024 | 96,000.00 |
| Sep 30, 2024 | 216,000.00 |
| Jun 30, 2024 | 196,000.00 |
| Mar 31, 2024 | 134,000.00 |
| Dec 31, 2023 | 379,000.00 |
| Sep 30, 2023 | 225,000.00 |
| Jun 30, 2023 | 85,000.00 |
| Mar 31, 2023 | -196,000.00 |
| Dec 31, 2022 | 275,000.00 |
| Sep 30, 2022 | 89,000.00 |
| Jun 30, 2022 | -100,000.00 |
| Mar 31, 2022 | -92,000.00 |
| Dec 31, 2021 | 32,000.00 |
| Sep 30, 2021 | 17,000.00 |
| Jun 30, 2021 | 25,000.00 |